Published in Br Med J on April 06, 1957
Iatrogenic alterations of immunologic surveillance in man and their influence on malignancy. Transplant Rev (1971) 2.94
Loss of Gastro-intestinal-specific Antigen in Neoplasia. Br Med J (1962) 2.59
Cancer immunotherapy--revisited. Nat Rev Drug Discov (2011) 2.26
Malignant tumors arising de novo in immunosuppressed organ transplant recipients. Transplantation (1972) 1.80
Study of TLR3, TLR4 and TLR9 in breast carcinomas and their association with metastasis. BMC Cancer (2010) 1.53
Evolving insights in the pathogenesis and therapy of cutaneous T-cell lymphoma (mycosis fungoides and Sezary syndrome). Br J Haematol (2011) 1.47
CAM and NK Cells. Evid Based Complement Alternat Med (2004) 1.42
POLE Proofreading Mutations Elicit an Antitumor Immune Response in Endometrial Cancer. Clin Cancer Res (2015) 1.27
Control of the immune response by pro-angiogenic factors. Front Oncol (2014) 1.26
Novel technologies and emerging biomarkers for personalized cancer immunotherapy. J Immunother Cancer (2016) 1.22
Tumor necrosis serum induces a serologically distinct population of NK cells. J Exp Med (1979) 1.15
How Do CD4(+) T Cells Detect and Eliminate Tumor Cells That Either Lack or Express MHC Class II Molecules? Front Immunol (2014) 1.14
Translating tumor antigens into cancer vaccines. Clin Vaccine Immunol (2010) 1.09
Antitumour actions of interferons: implications for cancer therapy. Nat Rev Cancer (2016) 1.08
CD4+ T lymphocyte ablation prevents pancreatic carcinogenesis in mice. Cancer Immunol Res (2014) 1.06
Immunological ignorance of solid tumors. Springer Semin Immunopathol (2005) 1.05
Combinations of immunotherapy and radiation in cancer therapy. Front Oncol (2014) 1.01
Cancer immunotherapy: are we there yet? Exp Hematol Oncol (2013) 0.98
Aging, cancer, and cancer vaccines. Immun Ageing (2012) 0.98
A critical analysis of the tumour immunosurveillance controversy for 3-MCA-induced sarcomas. Br J Cancer (2009) 0.98
Cancer immunotherapy in clinical practice -- the past, present, and future. Chin J Cancer (2014) 0.98
Revisiting immunosurveillance and immunostimulation: Implications for cancer immunotherapy. J Transl Med (2005) 0.97
Rational combinations of immunotherapeutics that target discrete pathways. J Immunother Cancer (2013) 0.95
Review: cancer-induced autoimmunity in the rheumatic diseases. Arthritis Rheumatol (2015) 0.94
In vitro induction of tumor-specific immunity. I. Parameters of activation and cytotoxic reactivity of mouse lymphoid cells immunized in vitro against syngeneic and allogeneic plasma cell tumors. J Exp Med (1973) 0.94
Malignant lymphoma and extensive viral wart formation in a patient with intestinal lymphangiectasia and lymphocyte depletion. Postgrad Med J (1977) 0.92
Methodological issues for determining intervals of subsequent cancer screening. Epidemiol Health (2014) 0.92
Cancer immunotherapy: the role regulatory T cells play and what can be done to overcome their inhibitory effects. Curr Mol Med (2009) 0.91
Cancer immunotherapy: nanodelivery approaches for immune cell targeting and tracking. Front Chem (2014) 0.89
Expression of RAGE and HMGB1 in thymic epithelial tumors, thymic hyperplasia and regular thymic morphology. PLoS One (2014) 0.89
A test for mutation theory of cancer: carcinogenesis by misrepair of DNA damaged by 4-nitroquinoline 1-oxide. Br J Cancer (1977) 0.88
Chronic Inflammation: Synergistic Interactions of Recruiting Macrophages (TAMs) and Eosinophils (Eos) with Host Mast Cells (MCs) and Tumorigenesis in CALTs. M-CSF, Suitable Biomarker for Cancer Diagnosis! Cancers (Basel) (2014) 0.87
Cell-Mediated Immune Responses of Preleukemic AKR Mice. Infect Immun (1974) 0.85
Bridging innate and adaptive antitumor immunity targeting glycans. J Biomed Biotechnol (2010) 0.84
Anti-tumor immunity: myeloid leukocytes control the immune landscape. Cell Immunol (2012) 0.84
Checkpoint modulation--A new way to direct the immune system against renal cell carcinoma. Hum Vaccin Immunother (2015) 0.83
Vaccine prevention of cancer: can endogenous antigens be targeted? Cancer Prev Res (Phila) (2010) 0.83
Can tissue-based immune markers be used for studying the natural history of cancer? Ann Epidemiol (2012) 0.83
Immunotherapy for solid tumors--a review for surgeons. J Surg Res (2013) 0.83
The delicate balance of melanoma immunotherapy. Clin Transl Immunology (2013) 0.83
Immune cell recruitment and cell-based system for cancer therapy. Pharm Res (2007) 0.83
Development and characterization of a preclinical model of breast cancer lung micrometastatic to macrometastatic progression. PLoS One (2014) 0.82
Glyco-engineered anti-EGFR mAb elicits ADCC by NK cells from colorectal cancer patients irrespective of chemotherapy. Br J Cancer (2014) 0.81
Sarcoma immunotherapy: past approaches and future directions. Sarcoma (2014) 0.81
Lymphopenia and its association with survival in patients with locally advanced cervical cancer. Gynecol Oncol (2015) 0.81
The concept of immune surveillance against tumors. The first theories. Oncotarget (2016) 0.80
Sarcoid-like lymphadenopathy in malignant teratoma. Postgrad Med J (1983) 0.80
New roads open up for implementing immunotherapy in mesothelioma. Clin Dev Immunol (2012) 0.80
Epithelial delamination and migration: lessons from Drosophila. Cell Adh Migr (2011) 0.80
Immunologic mechanisms in RCC and allogeneic renal transplant rejection. Nat Rev Urol (2010) 0.79
Dynamics of the cell-mediated immune response to tumour growth. Philos Trans A Math Phys Eng Sci (2017) 0.79
Beneficial autoimmunity at body surfaces - immune surveillance and rapid type 2 immunity regulate tissue homeostasis and cancer. Front Immunol (2014) 0.79
Associations between allergies and risk of hematologic malignancies: results from the VITamins and lifestyle cohort study. Am J Hematol (2013) 0.79
Immunotherapy for prostate cancer: False promises or true hope? Cancer (2016) 0.78
Tumor-primed NK cells: waiting for the green light. Front Immunol (2013) 0.77
Impaired gp100-Specific CD8(+) T-Cell Responses in the Presence of Myeloid-Derived Suppressor Cells in a Spontaneous Mouse Melanoma Model. J Invest Dermatol (2015) 0.77
Cancer as an immune-mediated disease. Immunotargets Ther (2012) 0.77
Current modalities in cancer immunotherapy: Immunomodulatory antibodies, CARs and vaccines. Pharmacol Ther (2017) 0.76
Targeting cancer-related inflammation in the era of immunotherapy. Immunol Cell Biol (2017) 0.75
Chimeric antigen receptors and bispecific antibodies to retarget T cells in pediatric oncology. Pediatr Blood Cancer (2015) 0.75
Self-reported prior lung diseases as risk factors for non-small cell lung cancer in Mexican Americans. J Immigr Minor Health (2013) 0.75
Cross-platform comparison of independent datasets identifies an immune signature associated with improved survival in metastatic melanoma. Oncotarget (2016) 0.75
Cancer vaccines at an inflexion point: what next? J Transl Med (2011) 0.75
A Perspective of Immunotherapy for Breast Cancer: Lessons Learned and Forward Directions for All Cancers. Breast Cancer (Auckl) (2015) 0.75
A Dynamic Model of Immune Responses to Antigen Presentation Predicts Different Regions of Tumor or Pathogen Elimination. Cell Syst (2017) 0.75
IL-13 from intraepithelial lymphocytes regulates tissue homeostasis and protects against carcinogenesis in the skin. Nat Commun (2016) 0.75
The Sweet Side of Immune Evasion: Role of Glycans in the Mechanisms of Cancer Progression. Front Oncol (2016) 0.75
How Cancers Escape Immune Destruction and Mechanisms of Action for the New Significantly Active Immune Therapies: Helping Nonimmunologists Decipher Recent Advances. Oncologist (2016) 0.75
Immunotherapy and radiation in glioblastoma. J Neurooncol (2017) 0.75
Pathways of tumor development and progression in drug-induced nonmelanoma skin cancer: a new hope or the next great confusion? Wien Med Wochenschr (2014) 0.75
Immunological consequences of ageing microvascular hemodynamic changes in view of cancer development and treatment. Oncotarget (2017) 0.75
Cancer Immunoprevention and Public Health. Front Public Health (2017) 0.75
A computational multiscale agent-based model for simulating spatio-temporal tumour immune response to PD1 and PDL1 inhibition. J R Soc Interface (2017) 0.75
Genetic interaction between influenza viruses. Nature (1953) 10.85
Role of the thymus and related organs in immunity. Br Med J (1962) 2.25
The future of medical research. Lancet (1953) 1.92
SOMATIC MUTATION AND CHRONIC DISEASE. Br Med J (1965) 1.85
Cancer: a biological approach. III. Viruses associated with neoplastic conditions. IV. Practical applications. Br Med J (1957) 1.74
IMMUNOLOGICAL FACTORS IN THE PROCESS OF CARCINOGENESIS. Br Med Bull (1964) 1.72
Autoimmune disease--experimental and clinical. Proc R Soc Med (1962) 1.71
Leukemia as a problem in preventive medicine. N Engl J Med (1958) 1.71
Genetics of virulence in influenza viruses. Nature (1954) 1.65
A DARWINIAN APPROACH TO IMMUNITY. Nature (1964) 1.51
Recurrent Kaposi's varicelliform eruption in an adult. Lancet (1951) 1.34
Auto-immune disease. II. Pathology of the immune response. Br Med J (1959) 1.32
EXPERIMENTAL PRODUCTION OF AUTO-ANTIBODIES OR OF AUTO-IMMUNE DISEASE. Br Med Bull (1963) 1.03
Auto-immune disease. I. Modern immunological concepts. Br Med J (1959) 0.99
The pattern of disease in childhood. Australas Ann Med (1952) 0.99
The mechanism of immunity. Sci Am (1961) 0.97
Virus classification and nomenclature. Ann N Y Acad Sci (1953) 0.97
Graft versus host reactions on the chorioallantoic membrane of the chick embryo. Nature (1960) 0.96
The newer approach to immunity in its bearing on medicine and biology. Br Med J (1954) 0.95
Ecology of virus diseases. Br Med Bull (1953) 0.91
Virulence in animal viruses. Lancet (1954) 0.90
Recent work on the intrinsic qualities of influenza virus; somatic and genetic aspects. Bull World Health Organ (1953) 0.85
The seeds of time; the impact of microbiology on human affairs since Lister's day. Med J Aust (1952) 0.76
General discussion of virus nomenclature. Ann N Y Acad Sci (1953) 0.75
Autoimmune disease. Med J Aust (1962) 0.75
Influenza virus group. Ann N Y Acad Sci (1953) 0.75
Virus genetics. Br Med Bull (1959) 0.75
PATHOLOGY OF THE THYMUS.. WITH SPECIAL REFERENCE TO AUTOIMMUNE DISEASE. Northwest Med (1964) 0.75
Ecology of virus diseases. Caribb Med J (1953) 0.75
The new laboratory approach to poliomyelitis. Med J Aust (1952) 0.75